Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 8/20 | 0.72 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026332 | 0.83 | CACNA2D1 (0.73) | CACNA2D1HTTGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL6026329 | 0.81 | HTT (0.62) | CACNA2D1HTTGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL24173232 | 0.77 | CACNA2D1 (1.00) | CACNA2D1TSHRKDM4E | |
| SCHEMBL24172788 | 0.74 | CACNA2D1 (0.73) | CACNA2D1KDM4E | |
| SCHEMBL6081986 | 0.73 | HTT (0.52) | CACNA2D1HTTGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL6082444 | 0.73 | CACNA2D1 (0.55) | CACNA2D1HTTALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL6082653 | 0.73 | CACNA2D1 (0.59) | CACNA2D1HTTGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL6082602 | 0.73 | CACNA2D1 (0.59) | CACNA2D1HTTALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL6082187 | 0.69 | CACNA2D1 (0.54) | CACNA2D1HTTALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL6026147 | 0.69 | CACNA2D1 (0.56) | CACNA2D1HTTGAAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264420-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2006-11-23 | — | — | US | disclosed |
| EP-1539180-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1539180-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040048853-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2004018058-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264420-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | CACNA2D1 3969/4885HTT 2077/4885GAA 314/4885 |
| US-20040048853-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | CACNA2D1 3969/4885HTT 2077/4885GAA 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.